免疫相关不良事件可预测帕博利珠单抗在尿路上皮癌患者中的治疗疗效。 - Suppr

Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients.

作者信息

Kawai Taketo, Sato Yusuke, Makino Katsuhiro, Yamada Yuta, Nomiya Akira, Nakamura Masaki, Yamada Daisuke, Suzuki Motofumi, Igawa Yasuhiko, Kume Haruki

机构信息

Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

出版信息

Eur J Cancer. 2019 Jul;116:114-115. doi: 10.1016/j.ejca.2019.05.017. Epub 2019 Jun 10.

DOI:10.1016/j.ejca.2019.05.017

PMID:31195355

Abstract

摘要

相似文献

Eur J Cancer. 2019 Jul;116:114-115. doi: 10.1016/j.ejca.2019.05.017. Epub 2019 Jun 10.

Pembrolizumab for Advanced Urothelial Carcinoma.

N Engl J Med. 2017 Jun 8;376(23):2302-3. doi: 10.1056/NEJMc1704612.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.

[Cochrane Rapid Review: the immune checkpoint inhibitor pembrolizumab versus chemotherapy for the treatment of advanced urothelial carcinoma].

Urologe A. 2019 Jan;58(1):45-48. doi: 10.1007/s00120-018-0838-5.

Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.

Oncology. 2020;98(4):237-242. doi: 10.1159/000505340. Epub 2020 Jan 14.

Recent advances in medical therapy for metastatic urothelial cancer.

Int J Clin Oncol. 2018 Aug;23(4):599-607. doi: 10.1007/s10147-018-1260-0. Epub 2018 Mar 20.

First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.

BJU Int. 2019 Apr;123(4):563-565. doi: 10.1111/bju.14627. Epub 2018 Dec 9.

Immune checkpoint inhibition in urothelial carcinoma.

Lancet. 2020 May 16;395(10236):1522-1523. doi: 10.1016/S0140-6736(20)30847-3.

Editorial Comment to Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.

Int J Urol. 2022 Jul;29(7):655. doi: 10.1111/iju.14889. Epub 2022 Mar 31.

First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.

J Oncol Pharm Pract. 2020 Jan;26(1):216-219. doi: 10.1177/1078155219835006. Epub 2019 Mar 4.

引用本文的文献

Cancers (Basel). 2024 Aug 31;16(17):3045. doi: 10.3390/cancers16173045.

Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center.

Cancers (Basel). 2024 Jun 18;16(12):2246. doi: 10.3390/cancers16122246.

Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis.

J Immunother Cancer. 2024 Mar 7;12(3):e008806. doi: 10.1136/jitc-2024-008806.

Young patients show poor efficacy for immune checkpoint inhibitor combined therapy in metastatic gastrointestinal cancers.

Front Oncol. 2023 May 3;13:1155019. doi: 10.3389/fonc.2023.1155019. eCollection 2023.

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.

Onco Targets Ther. 2022 Nov 5;15:1321-1330. doi: 10.2147/OTT.S389138. eCollection 2022.

Cancer Sci. 2022 Nov;113(11):3912-3921. doi: 10.1111/cas.15539. Epub 2022 Sep 2.

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.

Cancer Manag Res. 2022 May 3;14:1641-1651. doi: 10.2147/CMAR.S360473. eCollection 2022.

Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis.

J Immunother Cancer. 2022 Feb;10(2). doi: 10.1136/jitc-2021-003965.

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.

Cancer Manag Res. 2021 Oct 24;13:8049-8056. doi: 10.2147/CMAR.S333823. eCollection 2021.

Cancer Immunol Immunother. 2021 Sep;70(9):2559-2576. doi: 10.1007/s00262-020-02803-5. Epub 2021 Feb 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献